Abstract
The aim of this study is to identify risk factors for analgesic use following liver biopsy. In all, 121 consecutive biopsies were examined prospectively. Five variables were selected that might predict analgesia use: (1) anxiety, (2) request for sedation, (3) chronic use of addictive medications, (4) previous intravenous drug use, and (5) analgesia requirement with previous biopsies. Analgesia and narcotic requirement after liver biopsy were 35% and 15%, respectively. There was a lower average age (43 vs 47) (P = 0.03) and a higher Knodell score (7.2 vs 5.8) (P = 0.04) in those that required analgesics. The diagnosis of HCV (P = 0.007), previous intravenous drug abuse (IVDA) (P = 0.0001), request for medications before biopsy (P = 0.02), anxiety expressed (P = 0.0002), and chronic use of addictive medications (P = 0.03) predicted analgesia use. Previous IVDA (OR 9.3) and anxiety (OR 3.9) are predictive of pain medication use. In conclusion, patient characteristics play an important role in pain medication requirement after liver biopsy. If pain after liver biopsy is to be reduced, one has to understand the predisposing factors. Further studies utilizing behavior modification are warranted.
Similar content being viewed by others
REFERENCE
Babb RR, Jackman RJ: Needle biopsy of the liver: A critique of four currently available methods. West J Med 150:39–42, 1989
Van Leeuwan DJ, Wilson L, Crowe DR: Liver biopsy in the mid-1990: Questions and answers. Semin Liver Dis 15:340–359, 1995
Janes CH, Lindor KD: Outcome of patients hospitalized for complications after outpatient liver biopsy. Ann Intern Med 118:96–98, 1993
McGill DB, Rakela J, Zinsmeister AR, Ott BJ: A 21-year experience with major hemorrhage after percutaneous liver biopsy. Gastroenterology 99:1396–1400, 1990
Mahal AS, Knauer CM, Gregory PB: Bleeding after liver biopsy. West J Med 134:11–14, 1981
Perrault J, McGill DB, Ott BJ, Taylor WF: Liver biopsy: complications in 1000 inpatients and outpatients. Gastroenterology 74:103–106, 1978
Castera L, Negre I, Samii K, Buffet C: Pain experienced during percutaneous liver biopsy. Hepatology 30:1529–1530, 1999
Pasha T, Gabriel S, Therneau T, Dickson R, Lindor KD: Cost-effectiveness of ultrasound-guided liver biopsy. Hepatology 27:1220–1226, 1998
Lindor KD, Bru C, Jorgensen RA, Rakela J, Bordas JM, Gross JB, Rodes J, Mcgill DB, Reading CC, James EM, Charboneau JW, Ludwig J, Batts KP, Zinsmeister AR: The role of ultrasonography and automatic-needle biopsy in outpatient percutaneous liver biopsy. Hepatology 23:1079–1083, 1996
Riley TR: How often does ultrasound marking change the liver biopsy site? Am J Gastroenterol 94:3320–3322, 1999
Smith CI, Reddy R: Cost-effectiveness of ultrasonography in percutaneous liver biopsy. Hepatology 29:610, 1999 (letter)
Alexander JA, Smith BJ: Midazolam sedation for percutaneous liver biopsy. Dig Dis Sci 38:2209–2211, 1993
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Riley, T.R. Predictors of Pain Medication Use After Percutaneous Liver Biopsy. Dig Dis Sci 47, 2151–2153 (2002). https://doi.org/10.1023/A:1020110621854
Issue Date:
DOI: https://doi.org/10.1023/A:1020110621854